4D Molecular Therapeutics, Inc.

FDMT Nasdaq CIK: 0001650648

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Mailing Address 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Phone 5105052680
Fiscal Year End 1231
EIN 473506994

Financial Overview

FY2025

$566.71M
Total Assets
$61.05M
Total Liabilities
$510.61M
Stockholders' Equity
$149.34M
Cash & Equivalents
$-2.42
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 30, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
10-K Annual financial report March 18, 2026 View on SEC
8-K Current report of material events March 18, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC

Annual Reports

10-K March 18, 2026
  • Proprietary Therapeutic Vector Evolution platform for optimized gene delivery and diverse pipeline across multiple therapeutic areas.
  • Strong cash position of $300.8 million at year-end 2025, providing an estimated operational runway into late 2027.
View Analysis

Insider Trading

SELL 2 insiders 5 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.